Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Current Assets (2016 - 2026)

Pharma-Bio Serv's Current Assets history spans 16 years, with the latest figure at $13.3 million for Q1 2026.

  • For Q1 2026, Current Assets fell 14.23% year-over-year to $13.3 million; the TTM value through Jan 2026 reached $13.3 million, down 14.23%, while the annual FY2025 figure was $13.4 million, 14.73% down from the prior year.
  • Current Assets reached $13.3 million in Q1 2026 per PBSV's latest filing, roughly flat from $13.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $21.0 million in Q1 2022 to a low of $13.2 million in Q3 2025.
  • Average Current Assets over 5 years is $17.3 million, with a median of $18.8 million recorded in 2024.
  • Peak YoY movement for Current Assets: dropped 28.52% in 2022, then increased 0.75% in 2023.
  • A 5-year view of Current Assets shows it stood at $19.9 million in 2022, then decreased by 2.72% to $19.4 million in 2023, then decreased by 19.08% to $15.7 million in 2024, then dropped by 14.73% to $13.4 million in 2025, then decreased by 0.47% to $13.3 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Current Assets are $13.3 million (Q1 2026), $13.4 million (Q4 2025), and $13.2 million (Q3 2025).